The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma-Reference-Cited by-同舟云学术

The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma

Published:2022-04-01 Issue: Volume: Page:1-9
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Suh Kangho¹,Carlson Josh J²,Xia Fang³,Williamson Todd³,Sullivan Sean D²

Affiliation:

1. School of Pharmacy, University of Pittsburgh, PA.

2. Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, School of Pharmacy, University of Washington, Seattle.

3. Bayer U.S. LLC, Whippany, NJ.

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Reference25 articles.

1. Efficacy of Larotrectinib inTRKFusion–Positive Cancers in Adults and Children

2. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types

3. Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers

4. TRKing Down an Old Oncogene in a New Era of Targeted Therapy

5. Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Weibull parametric model for survival analysis in women with endometrial cancer using clinical and T2-weighted MRI radiomic features;BMC Medical Research Methodology;2024-05-09

2. Integrative analysis of PTEN‐related hub genes and validating drug targets for colorectal cancer;Precision Medical Sciences;2024-02-16

3. Toward Best Practices for Economic Evaluations of Tumor-Agnostic Therapies: A Review of Current Barriers and Solutions;Value in Health;2023-11

4. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas;Cancer;2023-09-28